indication directory

MASH / NASH clinical trial intelligence

Trials are included only when the source condition or controlled indication mapping directly matches this disease area. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

indication

Association rule

source condition

NCT06160271

Source recordAI-normalized

Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH)

Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH) is a PHASE2 clinical asset sponsored by Central Hospital, Nancy, France in Non-alcoholic Steatohepatitis. SEO and diligence focus: PET scan of 68Ga-FAPI, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI analysis

Indication: Non-alcoholic Steatohepatitis

Modality: small molecule

Target: PET scan of 68Ga-FAPI

Sponsor: Central Hospital, Nancy, France

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 24, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Non-alcoholic Steatohepatitis

View original source fields

Condition raw: Non-alcoholic Steatohepatitis

Condition normalized: Non-alcoholic Steatohepatitis

Modality raw: small molecule

Modality normalized: small molecule

Target raw: PET scan of 68Ga-FAPI

Target normalized: PET scan of 68Ga-FAPI

Open report

NCT06338969

Source recordAI-normalized

The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Manifestation of Starvation Ketosis and Ketoacidosis in Patients With Nonalcoholic Steatohepatitis

The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Manifestation of Starvation Ketosis and Ketoacidosis in Patients With Nonalcoholic Steatohepatitis is a NA clinical asset sponsored by The Society of Bariatric and Metabolic Surgeons of Kazakhstan in Obesity, Morbid, NASH, Ketosis, Keto Acidosis, Carbohydrate Metabolism Disorder. SEO and diligence focus: Carbohydrate Restriction after a Gastric Bypass, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI analysis

Indication: Obesity, Morbid

Modality: protein therapy

Target: Carbohydrate Restriction after a Gastric Bypass

Sponsor: The Society of Bariatric and Metabolic Surgeons of Kazakhstan

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: NASH

View original source fields